PMID: 8581384Oct 1, 1995Paper

Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII

Journal of Hematotherapy
L M WeinerR K Alpaugh

Abstract

Bispecific monoclonal antibodies (BsmAb) can be used to specifically target tumor cells for cytotoxicity mediated by defined effector cells. One such BsmAb, 2B1, targets the extracellular domains of both the c-erbB-2 protein product of the HER-2/neu oncogene and Fc gamma RIII (CD16), the Fc gamma receptor expressed by human natural killer cells, neutrophils, and differentiated mononuclear phagocytes. 2B1 promotes the conjugation of cells expressing these target antigens. It efficiently promotes the specific lysis of tumor cells expressing c-erbB-2 by human NK cells and macrophages over a broad concentration range. 2B1 selectively targets c-erbB-2-positive human tumor xenografts growing in immunodeficient SCID mice. Treatment of such mice with 2B1 plus interleukin 2 (IL-2) inhibits the growth of early, established human tumor xenografts overexpressing c-erbB-2. A phase I clinical trial of 2B1 has been initiated to determine the toxicity profile and maximum tolerated dose (MTD) of this BsmAb and to examine the biodistribution of the antibody and the biologic effects of treatment. Preliminary results of this trial indicate that the dose-limiting toxicity for patients with extensive prior bone marrow-toxic therapy is thrombocytopen...Continue Reading

References

Oct 1, 1989·Annals of Internal Medicine·R O Dillman
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vadhan-RajA N Houghton
Jan 1, 1988·Cancer Investigation·D M Segal, J R Wunderlich
Feb 1, 1994·ImmunoMethods·M W FangerP M Guyre

❮ Previous
Next ❯

Citations

Sep 17, 2013·Trends in Molecular Medicine·Barbara Seliger, Rolf Kiessling
Aug 1, 2000·Immunology Today·A B van SprielJ G van De Winkel
Feb 5, 2003·Advanced Drug Delivery Reviews·Ying Cao, Laura Lam
Jun 6, 2000·Advanced Drug Delivery Reviews· de Leij LB J Kroesen
Dec 3, 1998·Research in Immunology·C F Hendriksen, W de Leeuw
Nov 22, 1997·Current Opinion in Immunology·A M Scott, S Welt
Apr 1, 1997·Current Opinion in Immunology·M S HaydenJ A Ledbetter
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F RévillionJ P Peyrat
Sep 6, 2001·Biomolecular Engineering·J KriangkumM R Suresh
Sep 25, 2002·Critical Reviews in Oncology/hematology·R S RampaulI O Ellis
Jul 1, 2010·Expert Review of Clinical Pharmacology·Jijie Gu, Tariq Ghayur
Sep 24, 2008·Expert Opinion on Investigational Drugs·Philipp Kiewe, Eckhard Thiel
Jun 5, 2003·Expert Opinion on Investigational Drugs·Rita NahtaFrancisco J Esteva
Jul 5, 2005·Expert Opinion on Investigational Drugs·D L DrakemanP K Wallace
Feb 1, 1997·Journal of Chemotherapy·E A TorreR A Fulco
Feb 1, 2015·Molecular Immunology·Christoph SpiessPaul J Carter
Mar 6, 2007·The Journal of Allergy and Clinical Immunology·Ariel Munitz, Francesca Levi-Schaffer
Dec 30, 2003·International Journal of Cancer. Journal International Du Cancer·Peter RufHorst Lindhofer
Jul 17, 2010·Expert Reviews in Molecular Medicine·Marc E SeamanKimberly A Kelly
Jul 9, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Belén BlancoLuis Alvarez-Vallina
Feb 26, 2019·Frontiers in Oncology·Gaurav NayyarMitchell S Cairo
May 19, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philipp KieweMichael Untch
Feb 7, 2006·Cancer Letters·Rita Nahta, Francisco J Esteva
Nov 17, 1998·Bioconjugate Chemistry·Y Cao, M R Suresh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.